Compare Intercontinental Exchange Inc. Common Stock (ICE) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intercontinental Exchange Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? Intercontinental Exchange Inc. Common Stock trades at $155.53 (market cap $87.81B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: Intercontinental Exchange Inc. Common Stock is far larger — about 7.9× Repligen Corporation Common Stock's market cap, and Intercontinental Exchange Inc. Common Stock pays a 1.33% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals.
| ICE | RGEN | |
|---|---|---|
Market Cap | $87.81B | $11.14B |
Volume | 3,190,982 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $175.10 | $194.57 |
52-Week Low | $122.91 | $102.87 |
Enterprise Value | $105.72B | $11.02B |
Dividend Yield | 1.33% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intercontinental Exchange (ICE) trades at $156.42, down 0.64% on the day, with strong technical momentum showing bullish moving averages and key support at $155. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $1.90 versus $1.84, maintaining a three-quarter beat streak. Revenue growth accelerated to $13.4 billion in 2026 with net profit margin expanding to 30.07%, supported by record trading volumes in key markets.
ICE presents a compelling investment case with 89% analyst buy ratings and a $183.89 consensus price target implying 17.6% upside. The exchange operator's diversified platform and recurring revenue model provide stability, though investors should monitor competitive pressures and market volatility impacts. Strong cash flow generation and institutional support reinforce the bullish outlook despite near-term technical overbought conditions.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intercontinental Exchange Inc. Common Stock
Intercontinental Exchange provides technology and data services for financial institutions, corporations, and governments. Its businesses include exchanges and clearing, fixed-income data and analytics, and mortgage technology.
Read more on ICE →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
